108443-93-2

Basic information

• Product Name: N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE
• Synonyms: N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE;N'-HYDROXYTHIOPHENE-2-CARBOXIMIDAMIDE;THIOPHENE-2-AMIDOXIME
• CAS NO: 108443-93-2
• Molecular Formula: C₅H₆N₂OS
• Molecular Weight: 142.18
• Mol File: 108443-93-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE(108443-93-2)
• EPA Substance Registry System: N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE(108443-93-2)

Safety Data

• Hazardous Substances Data: 108443-93-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE is used as a reagent in organic synthesis for the preparation of various heterocyclic compounds. Its unique functional groups contribute to the formation of complex molecular structures, making it a valuable component in the creation of novel chemical entities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE is utilized for the synthesis of potential drug candidates. Its ability to be incorporated into diverse molecular frameworks positions it as a promising starting material for the development of new therapeutic agents.
Used in Medicinal Research:
N-HYDROXY-THIOPHENE-2-CARBOXAMIDINE is a subject of research for its medicinal properties due to its potential for various biological activities. Its exploration in this field aims to uncover new avenues for treatment and therapeutic intervention, capitalizing on its chemical versatility and biological potential.

Upstream product

• 1003-31-2 thiophene-2-carbonitrile 

Downstream Products

• 823195-13-7 5-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-isophthalic acid diethyl ester 
• 823195-12-6 3-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-benzoic acid ethyl ester 

Relevant articles and documents

Design, synthesis and biological activities of piperidine-spirooxadiazole derivatives as α7 nicotinic receptor antagonists

α: 7 nicotinic acetylcholine receptors (nAChRs) expressed in the nervous and immune systems have been suggested to play important roles in the control of inflammation. However, the lack of antagonist tools specifically inhibiting α7 nAChR impedes the validation of the channel as therapeutic target. To discover a selective α7 antagonist, we started a pharmacophore-based virtual screening and identified a piperidine-spirooxadiazole derivative T761–0184 that acts as a α7 antagonist. A series of novel piperidine-spirooxadiazole derivatives were subsequently synthesized and evaluated using two-electrode voltage clamp (TEVC) assay in Xenopus oocytes. Lead compounds from two series inhibited α7 with their IC50 values ranging from 3.3 μM to 13.7 μM. Compound B10 exhibited α7 selectivity over other α4β2 and α3β4 nAChR subtypes. The analysis of structure-activity relationship (SAR) provides valuable insights for further development of selective α7 nAChR antagonists.

Indazole-oxadiazole derivative, medicinal composition containing derivative, and application of derivative in tumor prevention

The invention discloses an indazole-oxadiazole derivative with the structure represented by general formula a shown in the description, or a pharmaceutically acceptable salt or solvate thereof. In the formula, X is O or N, Y is N, Z is N or O, and all groups are as defined in the description. The invention also discloses a medicinal composition adopting the derivative as an active component, and a use of the derivative. Compounds synthesized in the invention have an HIF-1 inhibition effect, and most of the compounds have a substantial HIF-1 inhibition effect, have strong in-vivo and in-vitro anti-HIF-1 effect on human colorectal carcinoma cell strains (HCT116) and other tumor cell strains, and can be used for treating tumor diseases.

Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

Hypoxia inducible factor-1 (HIF-1) is the key transcription factor of cellular response to hypoxia and plays a critical role in tumor metastasis. We describe here the discovery and a structure-activity relationship study of a series of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives as novel HIF-1 inhibitors. The two most promising compounds 4g and 4h inhibit HIF-1 transcription with IC50 values of 0.62 and 0.55 μM in vitro, respectively, and they exhibit more efficient HIF-1 inhibition in xenograft tumors than YC-1, a potential anticancer drug targeting HIF-1. In addition, they also remarkably prevent the hypoxia-driven migration of SKOV3 cells in vitro and tumor metastasis in vivo. Further investigation of the mechanism revealed that the two inhibitors could decrease HIF-1α and VEGF expression. These results suggest that our newly synthesized HIF-1 inhibitors 4g and 4h are potential therapeutic agents with which to treat tumor metastasis.

3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

Disclosed are 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, R2, A, B and D are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.